Published in J Phys Chem B on March 25, 2010
Effects of curvature and composition on α-synuclein binding to lipid vesicles. Biophys J (2010) 1.71
Biophysics of α-synuclein membrane interactions. Biochim Biophys Acta (2011) 1.08
Depth of α-synuclein in a bilayer determined by fluorescence, neutron reflectometry, and computation. Biophys J (2012) 1.06
Adsorption of α-synuclein to supported lipid bilayers: positioning and role of electrostatics. ACS Chem Neurosci (2013) 0.89
α-Synuclein-induced tubule formation in lipid bilayers. J Phys Chem B (2011) 0.88
Direct Detection of α-Synuclein Dimerization Dynamics: Single-Molecule Fluorescence Analysis. Biophys J (2015) 0.83
On-surface aggregation of α-synuclein at nanomolar concentrations results in two distinct growth mechanisms. ACS Chem Neurosci (2013) 0.82
Preparation and Characterization of Stable α-Synuclein Lipoprotein Particles. J Biol Chem (2016) 0.80
Effects of impaired membrane interactions on α-synuclein aggregation and neurotoxicity. Neurobiol Dis (2015) 0.80
Exploring the accessible conformations of N-terminal acetylated α-synuclein. FEBS Lett (2013) 0.79
Low alpha-synuclein levels in the blood are associated with insulin resistance. Sci Rep (2015) 0.78
Endosulfine-alpha inhibits membrane-induced α-synuclein aggregation and protects against α-synuclein neurotoxicity. Acta Neuropathol Commun (2017) 0.75
Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem (2006) 22.87
Impaired degradation of mutant alpha-synuclein by chaperone-mediated autophagy. Science (2004) 8.71
alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci U S A (1998) 8.41
NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry (1996) 6.47
Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83
Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem (1998) 5.81
Folding proteins in fatal ways. Nature (2003) 5.58
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron (1995) 4.78
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Synaptic vesicle depletion correlates with attenuated synaptic responses to prolonged repetitive stimulation in mice lacking alpha-synuclein. J Neurosci (2002) 4.01
A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem (2000) 3.97
Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons. J Neurosci (2000) 3.90
Structure of fully hydrated fluid phase lipid bilayers with monounsaturated chains. J Membr Biol (2006) 3.67
Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry (2000) 3.62
A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol (2003) 2.97
Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96
A broken alpha -helix in folded alpha -Synuclein. J Biol Chem (2003) 2.80
Lipid droplet binding and oligomerization properties of the Parkinson's disease protein alpha-synuclein. J Biol Chem (2001) 2.49
Structure of membrane-bound alpha-synuclein studied by site-directed spin labeling. Proc Natl Acad Sci U S A (2004) 2.33
Dependence of alpha-synuclein aggregate morphology on solution conditions. J Mol Biol (2002) 2.26
Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy. Biophys J (2006) 2.05
Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J Biol Chem (2001) 2.03
NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01
The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation. J Biol Chem (2003) 1.97
Synucleins in synaptic plasticity and neurodegenerative disorders. J Neurosci Res (1999) 1.93
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J Biol Chem (2003) 1.91
Proteasomal inhibition by alpha-synuclein filaments and oligomers. J Biol Chem (2004) 1.84
Regulation of phospholipase D2: selective inhibition of mammalian phospholipase D isoenzymes by alpha- and beta-synucleins. Biochemistry (1998) 1.80
The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by beta-amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol (1995) 1.71
Lipid binding inhibits alpha-synuclein fibril formation. J Biol Chem (2003) 1.64
Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease. J Mol Neurosci (2004) 1.63
Rapid anionic micelle-mediated alpha-synuclein fibrillization in vitro. J Biol Chem (2003) 1.62
Lipid demixing and protein-protein interactions in the adsorption of charged proteins on mixed membranes. Biophys J (2000) 1.59
Conformational behavior and aggregation of alpha-synuclein in organic solvents: modeling the effects of membranes. Biochemistry (2003) 1.51
An electrostatic/hydrogen bond switch as the basis for the specific interaction of phosphatidic acid with proteins. J Biol Chem (2007) 1.50
Exposure to long chain polyunsaturated fatty acids triggers rapid multimerization of synucleins. J Biol Chem (2001) 1.48
The rat brain synucleins; family of proteins transiently associated with neuronal membrane. Brain Res Mol Brain Res (1991) 1.46
Inhibition of fibrillization and accumulation of prefibrillar oligomers in mixtures of human and mouse alpha-synuclein. Biochemistry (2000) 1.45
Comparison of structure and dynamics of micelle-bound human alpha-synuclein and Parkinson disease variants. J Biol Chem (2005) 1.44
Structural reorganization of alpha-synuclein at low pH observed by NMR and REMD simulations. J Mol Biol (2009) 1.39
Phase behavior of synthetic phosphatidylglycerols and binary mixtures with phosphatidylcholines in the presence and absence of calcium ions. Biochemistry (1978) 1.34
A topological model of the interaction between alpha-synuclein and sodium dodecyl sulfate micelles. Biochemistry (2005) 1.33
What makes the bioactive lipids phosphatidic acid and lysophosphatidic acid so special? Biochemistry (2005) 1.33
Helical alpha-synuclein forms highly conductive ion channels. Biochemistry (2007) 1.24
Novel therapeutic strategies for the treatment of protein-misfolding diseases. Expert Rev Mol Med (2007) 1.18
alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease. FEBS Lett (2004) 1.14
Charge neutralization and collapse of the C-terminal tail of alpha-synuclein at low pH. Protein Sci (2009) 1.12
Domain formation induced by the adsorption of charged proteins on mixed lipid membranes. Biophys J (2004) 1.12
Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. Biophys J (2009) 1.09
Calcium-triggered membrane interaction of the alpha-synuclein acidic tail. Biochemistry (2006) 1.09
alpha-Synuclein interacts with phospholipase D isozymes and inhibits pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J Biol Chem (2002) 1.06
Age-associated changes in central nervous system glycerolipid composition and metabolism. Neurochem Res (2002) 1.02
Association of alpha-synuclein and mutants with lipid membranes: spin-label ESR and polarized IR. Biochemistry (2006) 0.93
Membrane-bound structure and energetics of alpha-synuclein. Proteins (2008) 0.91
Formation of three-dimensional structures in supported lipid bilayers. Biophys J (2007) 0.86
Interaction between dopamine and phospholipids. Studies of the substantia nigra in Parkinson disease patients. Arch Neurol (1975) 0.85
Effect of ions on the organization of phosphatidylcholine/phosphatidic acid bilayers. Biophys J (2007) 0.83
Controlling the charge and organization of anionic lipid bilayers: effect of monovalent and divalent ions. J Phys Chem B (2007) 0.82
Phospholipase D activity is regulated by product segregation and the structure formation of phosphatidic acid within model membranes. Biophys J (2007) 0.78
Path dependence of three-phase or two-phase end points in fluid binary lipid mixtures. J Phys Chem B (2009) 0.76
Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science (2006) 7.72
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity. Nat Genet (2009) 3.59
PGC-1α, a potential therapeutic target for early intervention in Parkinson's disease. Sci Transl Med (2010) 3.48
The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A (2007) 3.39
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech (2009) 2.16
Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing. Ann Neurol (2011) 2.11
Annular alpha-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain-derived membranes. Biochemistry (2002) 1.98
Yeast reveal a "druggable" Rsp5/Nedd4 network that ameliorates α-synuclein toxicity in neurons. Science (2013) 1.85
The N-terminal repeat domain of alpha-synuclein inhibits beta-sheet and amyloid fibril formation. Biochemistry (2003) 1.39
Small heat shock proteins protect against alpha-synuclein-induced toxicity and aggregation. Biochem Biophys Res Commun (2006) 1.32
Mechanisms of DJ-1 neuroprotection in a cellular model of Parkinson's disease. J Neurochem (2008) 1.27
Helical alpha-synuclein forms highly conductive ion channels. Biochemistry (2007) 1.24
Effect of surface treatment on diffusion and domain formation in supported lipid bilayers. Biophys J (2007) 1.21
Methionine sulfoxide reductase A protects dopaminergic cells from Parkinson's disease-related insults. Free Radic Biol Med (2008) 1.13
Clustering of alpha-synuclein on supported lipid bilayers: role of anionic lipid, protein, and divalent ion concentration. Biophys J (2009) 1.09
Effect of spermidine on misfolding and interactions of alpha-synuclein. PLoS One (2012) 1.03
Destabilization of DJ-1 by familial substitution and oxidative modifications: implications for Parkinson's disease. Biochemistry (2007) 0.99
Influence of lipid chemistry on membrane fluidity: tail and headgroup interactions. Biophys J (2006) 0.98
Identification of rotenone-induced modifications in alpha-synuclein using affinity pull-down and tandem mass spectrometry. Anal Chem (2006) 0.95
Infrared spectroscopy of fluid lipid bilayers. Anal Chem (2005) 0.92
Cyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study. Hum Mol Genet (2011) 0.91
In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. Biophys J (2013) 0.90
Reusable photocatalytic titanium dioxide-cellulose nanofiber films. J Colloid Interface Sci (2013) 0.89
α-Synuclein misfolding assessed with single molecule AFM force spectroscopy: effect of pathogenic mutations. Biochemistry (2013) 0.89
α-Synuclein-induced tubule formation in lipid bilayers. J Phys Chem B (2011) 0.88
Formation of three-dimensional structures in supported lipid bilayers. Biophys J (2007) 0.86
Effect of single amino acid substitution on oxidative modifications of the Parkinson's disease-related protein, DJ-1. Mol Cell Proteomics (2011) 0.85
Effect of ions on the organization of phosphatidylcholine/phosphatidic acid bilayers. Biophys J (2007) 0.83
Formation of complex three-dimensional structures in supported lipid bilayers. Langmuir (2009) 0.82
Controlling the charge and organization of anionic lipid bilayers: effect of monovalent and divalent ions. J Phys Chem B (2007) 0.82
Effect of salt concentration on membrane lysis pressure. Biochim Biophys Acta (2005) 0.81
Identification of the cysteine residue exposed by the conformational change in pig heart succinyl-CoA:3-ketoacid coenzyme A transferase on binding coenzyme A. Biochemistry (2007) 0.80
A high-performance renewable thermosetting resin derived from eugenol. ChemSusChem (2014) 0.76
Synthesis, characterization, and cure chemistry of renewable bis(cyanate) esters derived from 2-methoxy-4-methylphenol. Biomacromolecules (2013) 0.76
Path dependence of three-phase or two-phase end points in fluid binary lipid mixtures. J Phys Chem B (2009) 0.76
Printed optics: phantoms for quantitative deep tissue fluorescence imaging. Opt Lett (2016) 0.75
Using ionic strength to control liquid-ordered/liquid-disordered separation. J Phys Chem B (2007) 0.75
AgInS2 quantum dots for the detection of trinitrotoluene. Nanotechnology (2016) 0.75
Printed optics: phantoms for quantitative deep tissue fluorescence imaging: publisher's note. Opt Lett (2016) 0.75